Self-blood Glucose Monitoring Market Size to Surpass US$ 29.58 Billion by 2030 – Growth Plus Reports
Pune, Nov. 22, 2022 (GLOBE NEWSWIRE) — According to a new market research report titled, “Self-Blood Glucose Monitoring Market by Product Type (Testing Strips, Lancets, and Blood Glucose Meters), by Application (Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes), and by End User (Hospitals, Home Settings, and Diagnostic Centers) – Global Outlook & Forecast 2022-2030″ published by Growth Plus Reports, the Self-blood Glucose Monitoring Market is expected to grow at a CAGR of 7.50% from 2021 to reach US$ 29.58 billion by 2030.
Download Sample PDF Brochure of Self-blood Glucose Monitoring Market:
Innovation in products is going to enhance access to diabetes management due technological advancements, and the quality of treatment offered to patients. Access to information needed to both patients and healthcare professionals is one of the main advantages that technology has offered in the healthcare industry. With the beginning of EHRs (Electronic Healthcare Records), not only hospitals and clinics have gained benefits but also self-management for health conditions have become easily possible. Market players have launched many new innovative self-monitoring products with advanced features which has made supervising disease quite convenient.
Excerpts from ‘by Product Type’
The global self-blood glucose monitoring market is divided into
- Test Strips
- Blood Glucose Meters
based on product type. The market for self-blood glucose monitoring test strips has significantly increased over the years. Using diabetes test strips makes it simple to monitor blood sugar levels. Because non-diabetic people also use the gadget to monitor their health conditions, other segments including lancets and blood glucose meters will also experience profitable growth during the projection period. The blood glucose meters will experience steady increase in demand as it provides quick analyses of blood insulin levels for both hypoglycemic and hyperglycemic conditions.
Excerpts from ‘by Application’
- Type 1
- Type 2
- Gestational Diabetes
make up the market segments for glucose monitoring based on applications. Type 2 diabetes segment dominated the market in 2021. The main risk factor for type 2 diabetes are high blood pressure and obesity. Further, recurrent insulin resistance is a risk factor for type 2 diabetes, having high blood pressure appears to raise the probability of developing the disease. The presence of NEFA, glycerol, hormones, cytokines, proinflammatory chemicals, and other substances are involved in development of insulin resistance are present in higher proportions in obese people, which is another major risk factor for type 2 diabetes. The continued high prevalence of type 2 diabetes will increase the need for self-monitoring tools.
Excerpts from ‘by Region’
- North America
- Asia Pacific
- The Rest Of The World
regions make up the regional segments for self-blood glucose monitoring market. North America has the majority of market share in the global self-blood glucose monitoring market. Diabetes is highly prevalent in the region, and also has domicile of several market leaders, quick introduction of novel diagnostic and monitoring solutions in North America market is influencing the market growth. The International Diabetes Federation (IDF) projects that 51 million people in North America and the Caribbean have diabetes in 2021 and by 2045, this number will hit 63 million. The market for self-blood-glucose monitoring in Europe is characterized by a sharp rise in obesity, a large uptake of diabetes monitoring devices, and several developments. The large patient population, high rate of clinical trials and rapid product introductions in the market, which cause self-blood glucose monitoring market in Europe to occupy a prominent position in the global landscape.
Excerpts from ‘Competitive Landscape’
Some of the prominent players operating in the self-blood glucose monitoring market are
- Bionime Corporation
- Ypsomed Holding Ag
- Phc Holdings Corporation
- Trividia Health Inc.
- Lifescan Holdings Llc
- F. Hoffman-La Roche Ltd.
- Abbott Laboratories Inc.
- Arkray Inc.
- Braun Melsungen Ag
- Terumo Medical Corporation
Inquire Before Buying This Research Report:
Table of Content
- Market Ecosystem
- Timeline Under Consideration
- Base Year – 2021
- Historical Years – 2020
- Forecasted Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- GLOBAL SELF-BLOOD GLUCOSE MONITORING MARKET – ANALYSIS & FORECAST, BY PRODUCT TYPE
- Test Strips
- Blood Glucose Meters
- GLOBAL SELF-BLOOD GLUCOSE MONITORING MARKET – ANALYSIS & FORECAST, BY APPLICATION
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- GLOBAL SELF-BLOOD GLUCOSE MONITORING MARKET – ANALYSIS & FORECAST, BY END USER
- Home Settings
- Diagnostic Centers
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
- Distributor Landscape Assessment
- Pipeline Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Quickly Purchase Premium Copy of Self-blood Glucose Monitoring Market Report:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi Director, Market Insights Email: email@example.com Phone no: +91 96545 76783 Web: https://growthplusreports.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.